16 results about "Gastroparesis" patented technology

Embodiments include a method of diagnosing gastroparesis or suspected gastroparesis, the method comprising: obtaining data representing a time series of readings from gas sensing apparatus housed within a ingestible capsule device orally ingested by a subjected; processing the readings to detect one or more gastroparesis indicator spikes in the CO2 concentration with respect to time; based on the detected one or more gastroparesis indicator spikes in the CO2 concentration with respect to time, diagnosing gastroparesis or suspected gastroparesis.

The disclosure relates to methods for increasing gastric emptying in a human having gastroparesis.

A method for treating conditions of the gastrointestinal tract of a subject using a vibrating ingestible capsule ingested by the subject and activated in a targeted zone of the gastrointestinal tract of the subject. The conditions may include a sensation of gastric bloating, a sensation of straining during defecating, diarrhea and / or gastroparesis. The method is further suitable for reducing Bristol stool scores of fecal matter of the subject and for increasing a Bristol stool score of fecal matter of the subject.

The invention provides a traditional Chinese medicine external application composition for treating gastroparesis after brain injury and a preparation method thereof. The traditional Chinese medicine external application composition is prepared from the following components: rhizoma acori graminei, paederia scandens, radix polygoni multiflori preparata, aloe, gastrodia elata, semen aesculi, phyllanthus emblica, stephania tetrandra, turmeric, radix fici simplicissimae, fructus piperis longi, swertia pseudochinensis, rhizoma nardostachyos, lily, ginkgo leaves and cynanchum paniculatum. Dual mechanisms of neuroprotection and gastrointestinal motility regulation are creatively fused, central nervous injury can be improved through components such as rhizoma acori graminei and radix polygoni multiflori preparata, gastrointestinal hormone secretion and slow-wave pace-making functions can be synchronously regulated through components such as paederia scandens and turmeric, and compared with a conventional single-target treatment means, the traditional Chinese medicine composition is more suitable for a complex pathological mechanism of gastric paralysis after brain injury. Meanwhile, the preparation process is simple, the cost is low, external application avoids aggravation of gastrointestinal burdens, common western medicine side effects such as arrhythmia are avoided, clinical operation is convenient, patient tolerance is good, the gastric emptying recovery time is remarkably shortened, and the risk of complications such as aspiration pneumonia is reduced.

The invention provides a pharmaceutical composition for preventing and treating metabolic syndrome, resisting islet injury and promoting gastrointestinal function. The pharmaceutical composition is an oral preparation prepared from traditional Chinese medicinal raw materials or raw material extracts according to the following weight ratio. The raw material composition comprises the following medicinal materials and decoction pieces in parts by weight: 6-60 parts of fenugreek and 6-60 parts of inula flower. The traditional Chinese medicine composition comprises the following raw material extracts in parts by weight: 1-20 parts of fenugreek extract and 1-25 parts of inula flower extract. The pharmaceutical composition disclosed by the invention can effectively reduce blood sugar, triglyceride and cholesterol, improve insulin tolerance and hyperinsulinemia, improve glucose tolerance, relieve pancreas islet injury and promote gastrointestinal motility. The composition is good in safety, can be clinically used for preventing and treating the metabolic syndrome and protecting pancreas islet in the early stage, and can also be used for treating gastric paralysis and constipation.

The utility model discloses a double-interface side hole type nutrition pusher which comprises a nutrition tube, a supporting tube and a path finding guide tube, the supporting tube is movably arranged in the nutrition tube in a penetrating mode, and the path finding guide tube is movably arranged in the supporting tube in a penetrating mode. The nutrient canal is of a two-way joint structure and comprises a first sleeve joint formed by the near end of the nutrient canal and a second sleeve joint located on one side of the first sleeve joint, and a plurality of first interlayer side holes are formed in the near end of a canal body of the nutrient canal. The nutrient canal adopts the structural design of double interfaces, double cavities and the near-end side hole, the far end of the nutrient canal is arranged in the jejunum and can be used as the nutrient canal, the farthest end of the side hole is provided with an MARK mark, and the MARK does not exceed the pylorus when the nutrient canal is arranged, so that the side hole is positioned in the gastral cavity and is used for gastrointestinal decompression, and the nutrient canal is particularly suitable for patients suffering from gastric paralysis and needing enteral nutrition.

Described herein are methods for treating gastroparesis with intranasally-administered compositions comprising metoclopramide. The methods include periods of time in which a patient is not administered a composition comprising metoclopramide.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Disclosed herein is a method of treatment of an individual suffering from gastroparesis or delayed gastric emptying. In an embodiment, the method comprises selecting an individual for treatment with tradipitant based on a presence of a variant allele in one or more of the SLC4A4, SDK2, LCLAT1, SLC25A16, or CNTN1 genes of the individual; and administering to the selected individual tradipitant at a dose of 150-400 mg / day.

Disclosed herein are the use of thiazolidinediones for the treatment of digestive diseases including gastroparesis.

Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis.

The disclosure provides pharmaceutical formulations comprising d4-domperidone of the formula (I):or a pharmaceutically acceptable salt thereof. The formulations also contain (i) a glyceryl stearate, and a medium chain triglyceride; or (ii) a stearoyl polyoxyl glyceride, a nonionic poly(ethylene oxide) polymer, and a medium chain triglyceride; or (iii) a nonionic poly(ethylene oxide) polymer, and a polyethylene glycol. The disclosure also provides methods for treating a disorder that is gastroparesis, nausea apart from gastroparesis, vomiting apart from gastroparesis, nausea associated with gastroparesis, vomiting associated with gastroparesis, gastroesophageal reflux disease, insufficient lactation, or a combination thereof in a patient, comprising administering to the patient a formulation described herein. In some aspects, the disorder is gastroparesis. In other aspects, the disorder is gastroesophageal reflux disease. In further aspects, the disorder is insufficient lactation.

The disclosure provides methods for improving one or more gastrointestinal symptom in a human patient having cystic fibrosis and gastroparesis, comprising orally administering 10 mg to 120 mg of deudomperidone daily to the human patient.

Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3′R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3′-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Disclosed herein are compositions and methods for use in treating gastroparesis.

Systems and methods for implementation of a disposable miniaturized implant for treatment of Post-Operative Ileums (POI), a miniaturized implant for treating chronic GI dysmotility (e.g., dysphagia, gastroesophageal reflux disease (GERD), nausea, functional dyspepsia, blockage of transit, and gastroparesis, inflammatory bowel disease) and obesity, by providing electrical stimulation to the part of bowel going through surgery to expedite the healing process while recording the smooth muscle activities simultaneously, or providing stimulation on a treatment location of the GI tract or the branch of the vagus nerve. Systems and methods are also provided for non-invasive, transcutaneous stimulation of anatomy within the abdomen of the patient.